Large genomic deletions inactivate the BRCA2 gene in breast cancer families

被引:55
作者
Agata, S
Dalla Palma, M
Callegaro, M
Scaini, MC
Menin, C
Ghiotto, C
Nicoletto, O
Zavagno, G
Chieco-Bianchi, L
D'Andrea, E
Montagna, M
机构
[1] Dept Oncol & Surg Sci, Oncol Sect, I-35128 Padua, Italy
[2] Azienda Osped, IST Genova, Padua, Italy
[3] Azienda Osped, Clin Chirurg 2, Padua, Italy
关键词
D O I
10.1136/jmg.2005.032789
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: BRCA1 and BRCA2 are the two major genes responsible for the breast and ovarian cancers that cluster in families with a genetically determined predisposition. However, regardless of the mutation detection method employed, the percentage of families without identifiable alterations of these genes exceeds 50%, even when applying stringent criteria for family selection. A small but significant increase in mutation detection rate has resulted from the discovery of large genomic alterations in BRCA1. A few studies have addressed the question of whether BRCA2 might be inactivated by the same kinds of alteration, but most were either done on a relatively small number of samples or employed cumbersome mutation detection methods of variable sensitivity. Objective: To analyse 121 highly selected families using the recently available BRCA2 multiplex ligation dependent probe amplification (MLPA) technique. Results: Three different large genomic deletions were identified and confirmed by analysis of the mutant transcript and genomic characterisation of the breakpoints. Conclusions: Contrary to initial suggestions, the presence of BRCA2 genomic rearrangements is worth investigating in high risk breast or ovarian cancer families.
引用
收藏
页数:5
相关论文
共 30 条
[1]   Translocation and gross deletion breakpolints in human inherited disease and cancer I: Nucleotide composition and recomblination-assocliated motifs [J].
Abeysinghe, SS ;
Chuzhanova, N ;
Krawczak, M ;
Ball, EV ;
Cooper, DN .
HUMAN MUTATION, 2003, 22 (03) :229-244
[2]   Non-B DNA conformations, genomic rearrangements, and human disease [J].
Bacolla, A ;
Wells, RD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (46) :47411-47414
[3]   Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification [J].
Bunyan, DJ ;
Eccles, DM ;
Sillibourne, J ;
Wilkins, E ;
Thomas, NS ;
Shea-Simonds, J ;
Duncan, PJ ;
Curtis, CE ;
Robinson, DO ;
Harvey, JF ;
Cross, NCP .
BRITISH JOURNAL OF CANCER, 2004, 91 (06) :1155-1159
[4]   The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy [J].
Caligo, MA ;
Agata, S ;
Aceto, G ;
Crucianelli, R ;
Manoukian, S ;
Peissel, B ;
Scaini, MC ;
Sensi, E ;
Veschi, S ;
Cama, A ;
Radice, P ;
Viel, A ;
D'Andrea, E ;
Montagna, M .
HUMAN MUTATION, 2004, 24 (01) :100-101
[5]   Rapid detection of noval BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments [J].
Casilli, F ;
Di Rocco, ZC ;
Gad, S ;
Tournier, I ;
Stoppa-Lyonnet, D ;
Frebourg, T ;
Tosi, M .
HUMAN MUTATION, 2002, 20 (03) :218-226
[6]   Absence of rearrangements in the BRCA2 gene in human cancers [J].
Chin, SF ;
Wang, Q ;
Puisieux, A ;
Caldas, C .
BRITISH JOURNAL OF CANCER, 2001, 84 (02) :193-195
[7]  
Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251
[8]   Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance: the Modena Study Group proposal [J].
Federico, M ;
Maiorana, A ;
Mangone, L ;
Turchetti, D ;
Canossi, B ;
Cortesi, L ;
Romagnoli, R ;
Silingardi, V .
BREAST CANCER RESEARCH AND TREATMENT, 1999, 55 (03) :213-221
[9]   Bar code screening on combed DNA for large rearrangements of the BRCA1 and BRCA2 genes in French breast cancer families [J].
Gad, S ;
Klinger, M ;
Caux-Moncoutier, V ;
Pages-Berhouet, S ;
Gauthier-Villars, M ;
Coupier, I ;
Bensimon, A ;
Aurias, A ;
Stoppa-Lyonnet, D .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (11) :817-821
[10]   Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families [J].
Gad, S ;
Caux-Moncoutier, V ;
Pagès-Berhouet, S ;
Gauthier-Villars, M ;
Coupier, I ;
Pujol, P ;
Frénay, M ;
Gilbert, B ;
Maugard, C ;
Bignon, YJ ;
Chevrier, A ;
Rossi, A ;
Fricker, JP ;
Nguyen, TD ;
Demange, L ;
Aurias, A ;
Bensimon, A ;
Stoppa-Lyonnet, D .
ONCOGENE, 2002, 21 (44) :6841-6847